$-0.59 EPS Expected for Nabriva Therapeutics plc (NBRV); 2 Analysts Are Bullish Campbell Soup Company (CPB) Last Week

April 17, 2018 - By Winifred Garcia

Among 16 analysts covering Campbell Soup (NYSE:CPB), 2 have Buy rating, 7 Sell and 7 Hold. Therefore 13% are positive. Campbell Soup had 58 analyst reports since July 23, 2015 according to SRatingsIntel. The company was maintained on Monday, January 23 by Stifel Nicolaus. The stock of Campbell Soup Company (NYSE:CPB) has “Hold” rating given on Tuesday, February 21 by Stifel Nicolaus. Credit Suisse maintained Campbell Soup Company (NYSE:CPB) on Monday, April 16 with “Underperform” rating. As per Wednesday, November 23, the company rating was maintained by Credit Suisse. The stock of Campbell Soup Company (NYSE:CPB) has “Sector Perform” rating given on Monday, November 28 by RBC Capital Markets. As per Tuesday, July 18, the company rating was maintained by RBC Capital Markets. Credit Suisse maintained Campbell Soup Company (NYSE:CPB) rating on Friday, September 1. Credit Suisse has “Underperform” rating and $43 target. The firm has “Overweight” rating by JP Morgan given on Tuesday, January 19. On Thursday, May 25 the stock rating was maintained by Credit Suisse with “Sell”. The firm earned “Neutral” rating on Friday, September 4 by Citigroup. See Campbell Soup Company (NYSE:CPB) latest ratings:

16/04/2018 Broker: Credit Suisse Rating: Underperform New Target: $40 Maintain
01/03/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Underweight Old Target: $59 Downgrade
22/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $51.0 Maintain
20/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $50 New Target: $48 Maintain
14/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $55.0 Maintain
16/01/2018 Broker: Citigroup Rating: Buy New Target: $57.0 Upgrade
20/12/2017 Broker: Citigroup Rating: Hold New Target: $54.0 Maintain
15/12/2017 Broker: J.P. Morgan Rating: Hold New Target: $50.0
27/11/2017 Broker: Piper Jaffray Rating: Hold New Target: $49.0 Maintain
23/11/2017 Broker: UBS Rating: Sell Old Target: $42.00 New Target: $41.00 Maintain

Analysts expect Nabriva Therapeutics plc (NASDAQ:NBRV) to report $-0.59 EPS on May, 9.They anticipate $0.03 EPS change or 5.36% from last quarter’s $-0.56 EPS. After having $-0.60 EPS previously, Nabriva Therapeutics plc’s analysts see -1.67% EPS growth. The stock increased 7.96% or $0.39 during the last trading session, reaching $5.29. About 615,419 shares traded or 133.49% up from the average. Nabriva Therapeutics plc (NASDAQ:NBRV) has declined 53.70% since April 17, 2017 and is downtrending. It has underperformed by 65.25% the S&P500.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company has market cap of $194.23 million. The firm focuses on the pleuromutilin class of antibiotics. It currently has negative earnings. The Company’s lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections.

Among 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nabriva Therapeutics had 8 analyst reports since October 12, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, January 27 by Gabelli. Leerink Swann initiated Nabriva Therapeutics plc (NASDAQ:NBRV) on Tuesday, October 13 with “Outperform” rating. The rating was maintained by RBC Capital Markets on Thursday, November 12 with “Outperform”. Leerink Swann reinitiated Nabriva Therapeutics plc (NASDAQ:NBRV) on Thursday, October 27 with “Outperform” rating. Wedbush maintained the shares of NBRV in report on Wednesday, February 1 with “Outperform” rating. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, October 13. As per Tuesday, October 13, the company rating was initiated by Wedbush. Needham initiated Nabriva Therapeutics plc (NASDAQ:NBRV) rating on Monday, October 12. Needham has “Buy” rating and $15 target.

Since December 20, 2017, it had 1 buy, and 1 sale for $112,624 activity. 4,400 shares were bought by Mignini Luca, worth $200,351 on Wednesday, February 21. The insider Carolan Edward sold $312,975.

Campbell Soup Company, together with its subsidiaries, makes and markets food and beverage products. The company has market cap of $12.86 billion. It operates through three divisions: Americas Simple Meals and Beverages; Global Biscuits and Snacks; and Campbell Fresh. It has a 12.32 P/E ratio. The Americas Simple Meals and Beverages segment engages in the retail and food service of CampbellÂ’s condensed and ready-to-serve soups; Swanson broth and stocks; Prego pasta sauces; Pace Mexican sauces; CampbellÂ’s gravies, pastas, beans, and dinner sauces; Swanson canned poultry; Plum food and snacks; V8 juices and beverages; and CampbellÂ’s tomato juices.

Investors sentiment increased to 1.06 in Q4 2017. Its up 0.08, from 0.98 in 2017Q3. It increased, as 51 investors sold Campbell Soup Company shares while 148 reduced holdings. 66 funds opened positions while 144 raised stakes. 147.14 million shares or 7.00% more from 137.50 million shares in 2017Q3 were reported. Town And Country Fincl Bank And Tru Dba First Bankers Tru reported 0.16% in Campbell Soup Company (NYSE:CPB). Principal Fincl Group reported 383,185 shares or 0.02% of all its holdings. 139,086 are held by Arizona State Retirement Systems. New Mexico Educational Retirement Board holds 18,612 shares. Destination Wealth Mgmt accumulated 0.21% or 72,878 shares. Fairfield Bush & owns 4,300 shares or 0.06% of their US portfolio. Moreover, State Of Alaska Department Of Revenue has 0.06% invested in Campbell Soup Company (NYSE:CPB) for 56,375 shares. Huntington Bancshares reported 0.01% of its portfolio in Campbell Soup Company (NYSE:CPB). 10,278 are owned by Public Sector Pension Inv Board. Bokf Na holds 0.04% or 30,530 shares. Financial Architects reported 500 shares or 0% of all its holdings. Connor Clark Lunn Invest Ltd has invested 0.01% in Campbell Soup Company (NYSE:CPB). Advantus Capital holds 19,208 shares. Fmr Ltd invested in 5.01M shares. Private Advisor Grp Ltd Limited Liability Company holds 6,943 shares or 0.01% of its portfolio.

By1 Winifred Garcia